Recently, the product titled Gamma-Delta T Cell-Derived Exosomes submitted by Shenzhen Cell Valley Group has obtained official filing approval from the U.S. Food and Drug Administration (FDA), with the assigned Type II DMF number 044047. The filing holder is Shenzhen Cell Valley Biopharmaceuticals Co., Ltd.

Public records confirm this is the world’s first successful FDA Type II DMF filing for gamma-delta  T cell-derived exosomes. The achievement represents a major breakthrough and global leadership for Shenzhen Cell Valley in raw material production, quality research, process control and international regulatory compliance for immune cell-derived exosomes.

Forging a Next-Generation Extracellular Vesicle Drug Platform Based on γδ T Cell Exosomes

As a key subset bridging innate and adaptive immunity, γδ T cells function independently of conventional MHC antigen presentation, capable of broadly recognizing abnormal cells and mounting rapid immune responses. In recent years, γδ T cell-derived exosomes have emerged as a cutting-edge focus in cell therapy and exosome drug development, owing to their promising anti-tumor, immunomodulatory and drug delivery capabilities. Studies have verified their anti-tumor potential, as they can trigger tumor cell death via pathways including Fas/FasL and DR5/TRAIL.

Unlike conventional live cell therapies, exosomes serve as a cell-free therapeutic and delivery platform featuring superior stability, scalable production, low immunogenicity and strong tissue penetration.

Expanding the Immune Cell-Derived Exosome Portfolio: From NK to γδ T Exosomes

This DMF approval marks another important international compliance milestone for Shenzhen Cell Valley, following its earlier progress with NK cell-derived exosomes. The company has built a comprehensive platform covering cell source control, exosome isolation and purification, quality criteria, functional assessment, stability testing and industrial-scale production for exosomes derived from innate immune cells such as NK cells and γδ T cells.

Shenzhen Cell Valley noted that γδ T cell-derived exosomes carry molecules associated with immune recognition and cell cytotoxicity, and hold great potential for bioengineering. Going forward, the company will conduct in-depth research and accelerate product translation targeting tumor immunotherapy, inflammation regulation, tissue repair and novel drug delivery systems.

Elevating International Compliance Framework to Support Global Collaboration and IND/BLA Submissions

According to the FDA acknowledgement, this DMF may be cited and reviewed through official letters of authorization to support new drug applications, abbreviated new drug applications, investigational new drug applications (IND) and biologics license applications (BLA). Authorized partners can reference the filed documentation in subsequent regulatory submissions, delivering robust compliance backing for global clinical development and registration.

Building a Globally Leading Foundational Technology Platform for Cell and Gene Therapy

As a one-stop CRO/CDMO and clinical translation platform dedicated to cell and gene therapy, Shenzhen Cell Valley has established a diversified technological ecosystem encompassing retroviral vectors, lentiviral vectors, AAV, engineered virus-like particle (eVLP) delivery systems, NK cells, CAR-NK, CAR-T, γδ T cells, MSCs and exosomes. The latest FDA DMF filing further strengthens the company’s underlying technological layout spanning immune cells, exosomes, delivery systems and clinical translation.

Moving forward, aligned with global industry trends, Shenzhen Cell Valley will advance the standardization, large-scale production and international adoption of next-generation biotech platforms including exosomes, eVLPs and immune cell derivatives, helping Chinese original cell and gene therapy technologies gain traction across the globe.